Agenus Inc
AGEN4.380USD
-0.170-3.74%
收盘 09/19, 16:00（美东）报价延迟15分钟
131.42M总市值
亏损市盈率 TTM
关于 Agenus Inc 公司
Agenus Inc. 是一家免疫肿瘤学 (IO) 公司，专注于癌症和传染病，拥有一系列免疫药物。该公司专门开发激活人体免疫系统对抗癌症和感染的疗法。其产品线包括免疫调节抗体、过继细胞疗法（通过 MiNK Therapeutics, Inc.）和疫苗佐剂（通过 SaponiQx, Inc.）。其主要关注点是免疫肿瘤学，其多样化的产品线由其内部能力支持，包括现行良好生产规范 (cGMP) 制造和临床运营平台。其最先进的抗体候选药物是 botensilimab（一种多功能免疫细胞激活剂和人类 Fc 增强细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 阻断抗体 (AGEN1811)）和 balstilimab（一种程序性死亡受体-1 (PD-1) 阻断抗体）。其产品线包括几类免疫疗法：检查点抑制剂、免疫激活剂和肿瘤微环境调节剂。
公司简介
公司代码AGEN
公司名称Agenus Inc
上市日期Feb 04, 2000
CEODr. Garo H. Armen, Ph.D.
员工数量316
证券类型Ordinary Share
年结日Feb 04
公司地址3 Forbes Rd
城市LEXINGTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02421-7305
电话17816744400
网址https://agenusbio.com/
公司代码AGEN
上市日期Feb 04, 2000
CEODr. Garo H. Armen, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
16.30K
+83.18%
Ms. Susan B. Hirsch
Ms. Susan B. Hirsch
Independent Director
Independent Director
5.94K
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
16.30K
+83.18%
Ms. Susan B. Hirsch
Ms. Susan B. Hirsch
Independent Director
Independent Director
5.94K
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Non-cash royalty revenue
23.56M
97.88%
Other services
510.00K
2.12%
地区USD
名称
营收
占比
United States
23.56M
97.88%
Rest of world
510.00K
2.12%
业务
地区
业务USD
名称
营收
占比
Non-cash royalty revenue
23.56M
97.88%
Other services
510.00K
2.12%
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.95%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
其他
82.49%
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.95%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
其他
82.49%
股东类型
持股股东
占比
Investment Advisor
17.75%
Investment Advisor/Hedge Fund
4.62%
Research Firm
4.43%
Hedge Fund
2.84%
Individual Investor
1.71%
Venture Capital
0.19%
Family Office
0.17%
Bank and Trust
0.09%
其他
68.20%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
332
9.29M
33.90%
-3.65M
2025Q1
345
9.68M
35.51%
-3.04M
2024Q4
351
8.87M
37.81%
-3.86M
2024Q3
360
8.97M
41.48%
-3.09M
2024Q2
356
9.47M
44.86%
-4.33M
2024Q1
365
10.95M
52.48%
-2.79M
2023Q4
382
11.94M
62.90%
-111.48K
2023Q3
392
12.65M
70.00%
-689.92K
2023Q2
391
12.38M
73.61%
-974.75K
2023Q1
387
12.07M
75.08%
+236.97K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
2.55M
9.3%
+140.69K
+5.84%
Mar 31, 2025
Invus Public Equities Advisors, LLC
500.00K
1.82%
+500.00K
--
Mar 31, 2025
B. Riley Financial, Inc
756.96K
2.76%
+756.96K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
369.40K
1.35%
+34.14K
+10.18%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
5.86%
+103.10K
+6.85%
Mar 31, 2025
AQR Capital Management, LLC
441.49K
1.61%
+427.60K
+3080.28%
Mar 31, 2025
BofA Global Research (US)
200.35K
0.73%
+93.23K
+87.03%
Mar 31, 2025
Armen (Garo H.)
319.09K
1.16%
+68.31K
+27.24%
Jun 27, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0%
SPDR S&P Biotech ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.03%
iShares Russell 2000 Growth ETF
占比0%
SPDR S&P Biotech ETF
占比0%
iShares Russell 3000 ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
SPDR Portfolio MSCI Global Stock Market ETF
占比0%
Global X Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
公告日期
类型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
